On February 9, 2019, the so-called Falsified Medicines Directive came into force in the pharmaceutical industry. What are its benefits and obligations?
Dr. Anna Gawrońska, Head of the Standardization Center at ILiM: The market for counterfeit medicines purchased in Poland is estimated at 65 million euros. Counterfeiting generates high profits – globally, it is estimated at 90 billion dollars. Of course, we are talking about the criminals’ profits here. The losses, however, are obvious – a threat to the health and even the lives of patients. The World Health Organization (WHO) estimates that 120,000 school-age children in Africa die of malaria because they receive a medicine for this disease without an active substance. About 98 percent of online pharmacies are illegal. The way to curb this practice is Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 on the prevention of the entry into the legal supply chain of falsified medicinal products – the so-called Falsified Medicines Directive. Its goal is to seal this chain.
From February 9, 2019, pharmaceutical companies have new obligations. An extremely important element of this solution is GS1 standards. All newly released batches of medicinal products after February 9, 2019, will have to be marked with a GS1 DataMatrix two-dimensional code. Pharmaceutical companies will be responsible for introducing new code markings that will reflect the so-called unique identifier. This identifier will consist of the so-called product code, serial number, batch number (in Poland called a series), and expiration date. Additionally, pharmaceutical companies must enter this data into the European hub.
All necessary information that pharmaceutical companies must familiarize themselves with can be found on the websites of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products and GS1 Poland. Helpful data regarding cooperation with the European hub, as well as the possibilities of using the national database, are available on the website of the National Medicines Verification Organization – KOWAL.








